NEW YORK, Oct. 24, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc., (API), a private biopharmaceutical company that develops innovative targeted radio-immunotherapeutics, announced that the poster summarizing the results for Phase I study of Actimab-A, its antibody directed alpha emitter drug candidate, has won a first place poster presentation award at the 8th Annual Hematologic Malignancies 2012 Conference held in Houston, TX, from October 10-14. The award was presented to Dr. Joseph Jurcic of Memorial Sloan Kettering Cancer Center, the Primary Investigator in the trial, by the conference chairmen, Dr. Hagop Kantarjian, Chairman of the Department of Leukemia at MD Anderson Cancer Center and Dr. Emil Freireich of the Developmental Therapeutics department at MD Anderson.
The Hematologic Malignancies Conference is a premier meeting that focuses specifically on new advances and practical clinical applications in the field of hematologic malignancies. Almost 700 physicians and other healthcare specialists attended this year.
Actimab-A is being developed for the front line treatment of acute myeloid leukemia in older patients. The drug candidate was evaluated in a Phase I dose escalating trial at Memorial Sloan Kettering Cancer Center (MSKCC). The poster entitled "Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab in Acute Myeloid Leukemia (AML)" was presented at the Conference by Dr. Jurcic and summarizes key findings from the trial. The goal of the trial was to determine the maximum tolerated dose (MTD), toxicity, pharmacokinetics, and antileukemic activity of 225Ac-lintuzumab. It was a first-in-man, Phase I, dose-escalation trial.
This is the first study to show that therapy with a targeted a-particle generator is feasible in humans. The study has demonstrated that Actimab-A (Lintuzumab-Ac-225) has significant antileukemic activity across all dose levels and the drug candidate is now being further investigated in a multicenter Phase I/II trial in combination with low-dose cytarabine for older AML patients.
"We are very pleased that such a distinguished forum found the results of our drug candidate so compelling," said Jack Talley, CEO of Actinium. "This is a further confirmation that our development efforts on Actimab-A are progressing quickly and gaining recognition. We expect that our collaboration with Dr. Jurcic and other prominent physicians will continue to bring benefits to AML patients."
About Actinium 225
Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. The technology was first developed by Dr. David Scheinberg at Memorial Sloan Kettering Cancer Center.
About Lintuzumab (HuM195)
Lintuzumab is a monoclonal antibody that targets CD33, found on myeloid leukemia cells. It is the humanized version of M195, the antibody initially developed by Dr. David Scheinberg of Memorial Sloan Kettering Cancer Center.
About Acute Myeloid Leukemia
Acute Myeloid Leukemia is the most difficult to treat form of leukemia. The majority of patients are older than 60 and most of them do not qualify for the commonly used chemotherapy regimens and their median survival following diagnosis is about 2 months without treatment.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a New York, New York based biopharmaceutical company that develops innovative immunotherapeutics based on its proprietary platforms for the therapeutic utilization of radioimmunotherapy agents in association with monoclonal antibodies.
For more information:
Visit our web site www.actiniumpharmaceuticals.com or contact:
Jack Talley, CEO
Actinium Pharmaceuticals Inc.
Tel: (646) 459-4201
This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
SOURCE Actinium Pharmaceuticals